Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Marvel Research 002 LLC

Neither a doctor nor a teaching hospital

Research payments

$1,767,284

154 payments

Through program year 2025, Marvel Research 002 LLC is reported as receiving $1,767,284 in research payments, across 154 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $41,633 5
2024 Research $170,943 20
2023 Research $961,572 20
2022 Research $122,197 35
2021 Research $168,608 36
2020 Research $302,331 38

Breakdown

Who paid Research payments · program years 2020–2025
  1. GlaxoSmithKline, LLC. $1,163,718 40 payments
  2. AbbVie, Inc. $306,093 70 payments
  3. Allergan Inc. $199,881 19 payments
  4. Kyowa Kirin Pharmaceutical Development, Inc $38,989 6 payments
  5. Mitsubishi Tanabe Pharma Development America, Inc. $21,548 3 payments
  6. Sun Pharmaceutical Industries Inc. $19,635 10 payments
  7. Pfizer Inc. $12,528 2 payments
  8. Mitsubishi Tanabe Pharma America, Inc. $4,374 3 payments
  9. Myovant Sciences Inc. $519 1 payment
Studies the money was for Research payments · program years 2020–2025
  1. A Phase I/II Observer-Blind, Randomized, Multi-Center Trial to Evaluat $578,299 16 payments
  2. A Phase III, Open-Label, Randomized, Controlled, Multi-Country Study T $489,190 16 payments
  3. Androderm 24-Hr ABPM $130,360 13 payments
  4. M16-100 $124,239 19 payments
  5. A Multicentre Randomized, Double-Blind, Placebo-Controlled, Dose-Findi $96,230 8 payments
  6. Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study $91,950 25 payments
  7. A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men $75,939 22 payments
  8. Androderm 24-Hr ABPM $69,520 6 payments
  9. A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo controlled Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects with Moderate to Severe Atopic Dermatitis (AD) $38,989 6 payments
  10. Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) $13,205 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record